Silo Pharma announced it regained compliance with Nasdaq's minimum closing bid price requirement as of June 17, 2026, resolving a listing qualification matter. The company continues trading on the Nasdaq Capital Market while advancing its lead PTSD drug candidate SPC-15 toward clinical trials.